prof. dr. J.M. (Jaap) van Laar

Full Professor
prof. dr. J.M. (Jaap) van Laar
  • Rheumatology & Clinical Immunology



Jacob M. van Laar is Professor at the Department of Rheumatology and Clinical Immunology at UMC Utrecht, the Netherlands. After obtaining his MD and PhD degrees at Leiden University, he specialised in Internal Medicine and Rheumatology in Leiden University Medical Center and worked at the Department of Rheumatology as clinical academic in various roles from 1997-2007, interrupted by a postdoctoral research fellowship at the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, USA. From 2007 until 2013 he held a Chair in Clinical Rheumatology at Newcastle University, and post as honorary consultant rheumatologist at The James Cook University Hospital, Middlesbrough, UK. He has been working as Professor of Rheumatology at UMC Utrecht since 1 November 2013. His main research interests involve clinical and pathogenetic aspects of systemic sclerosis and rheumatoid arthritis, aimed at improving the outcome of patients with rheumatic diseases by innovative clinical-translational research.

Side Activities

  • Member EULAR Scientific Programme Committee (2018 - present)

    Ad hoc expert advice Central Board of Appeal (2018 - present)

    Chairman Concilium Dutch Society for Rheumatology (2014-present)

    Founding Member Stichting ARCH (2017-present)

    Member Scientific Advisory Board Edith Busch Stiftung (2015-present)

    Member of EUSTAR (EULAR Scleroderma Trials and Research) (2007-present) 

    Ad hoc consultant for pharmaceutical companies (2013 - present)

    Chair Society for Rheumatology Research Utrecht (2013 - 2019)


Fellowship and Awards

  • Marie Parijs prijs for pioneering work in the field of clinical stem cell research in rheumatic autoimmune diseases (2002, Leiden University Medical Center)

    ZonMW Clinical Fellow (2007)

    Fellow of the Royal College of Physicians Edinburgh (2009)

Research Output (269)

From “being at war” to “getting back on your feet”:A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation

Spierings Julia, de Bresser Carolijn J.M., van Rhijn-Brouwer Femke C.C., Pieterse Arwen, Vonk Madelon C., Voskuyl Alexandre E., de Vries-Bouwstra Jeska K., van Laar Jacob M., Kars Marijke C. okt 2020, In: Journal of Scleroderma and Related Disorders. 5 , p. 202-209

CXCL4 Links Inflammation and Fibrosis by Reprogramming Monocyte-Derived Dendritic Cellsin vitro

Silva-Cardoso Sandra C., Tao Weiyang, Angiolilli Chiara, Lopes Ana P., Bekker Cornelis P. J., Devaprasad Abhinandan, Giovannone Barbara, van Laar Jaap, Cossu Marta, Marut Wioleta, Hack Erik, de Boer Rob J., Boes Marianne, Radstake Timothy R. D. J., Pandit Aridaman 17 sep 2020, In: Frontiers in Immunology. 11

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate

Verhoeven Maxime M.A., Tekstra Janneke, Welsing Paco M.J., Pethö-Schramm Attila, Borm Michelle E.A., Bruyn George A.W., Bos Reinhard, Griep Ed N., Klaasen Ruth, van Laar Jacob M., Lafeber Floris P.J.G., Bijlsma Johannes W.J., de Hair Marjolein J.H., Jacobs Johannes W.G. 1 sep 2020, In: Rheumatology (Oxford, England). 59 , p. 2325-2333 9 p.

Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis:results of a long-term follow-up multicentre study

van Bijnen Sandra, de Vries-Bouwstra Jeska, van den Ende Cornelia H, Boonstra Maaike, Kroft Lucie, Geurts Bram, Snoeren Miranda, Schouffoer Anne, Spierings Julia, van Laar Jacob M, Huizinga Tom Wj, Voskuyl Alexandre, Marijt Erik, van der Velden Walter, van den Hoogen Frank Hj, Vonk Madelon C aug 2020, In: Annals of the Rheumatic Diseases. 79 , p. 1084-1089 6 p.

Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe:results from the first ERN ReCONNET survey

Talarico Rosaria, Marinello Diana, Bombardieri Stefano, Burmester Gerd, Fonseca Joao, Frank Charissa, Galetti Ilaria, Hachulla Eric, Houssiau Frederic, Mueller-Ladner Ulf, Schneider Matthias, Smith Vanessa, Turchetti Giuseppe, van Laar Jacob M, Vieira Ana, Cutolo Maurizio, Mosca Marta aug 2020, In: RMD Open. 6

The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation

Servaas N. H., Spierings J., Pandit A., van Laar J. M. 1 jul 2020, In: Clinical and Experimental Immunology. 201 , p. 34-39 6 p.

How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?

Spierings Julia, van den Ende Cornelia H M, Schriemer Rita M, Moens Hein J Bernelot, van der Bijl Egon A, Bonte-Mineur Femke, de Buck Marieke P D, de Kanter Meeke A E, Knaapen-Hans Hanneke K A, van Laar Jacob M, Mulder Udo D J, Potjewijd Judith, de Pundert Lian A J, Schoonbrood Thea H M, Schouffoer Anne A, Stel Alja J, Vercoutere Ward, Voskuyl Alexandre E, de Vries-Bouwstra Jeska K, Vonk Madelon C 1 jun 2020, In: Rheumatology (Oxford, England). 59 , p. 1226-1232 7 p.

Difficulté de prédire la réponse clinique au méthotrexate chez les patients atteints de polyarthrite rhumatoïde:revue systématique de la littérature

Roodenrijs Nadia M.T., van der Goes Marlies C., Welsing Paco M.J., Tekstra Janneke, van Laar Jacob M., Lafeber Floris P.J.G., Bijlsma Johannes W.J., Jacobs Johannes W.G. mei 2020, In: Revue du Rhumatisme (Edition Francaise). 87 , p. 169-180 12 p.

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA):study protocol for a pragmatic trial

van der Leeuw Matthijs S, Welsing Paco M J, de Hair Maria J H, Jacobs Johannes W G, Marijnissen Anne C A, Linn-Rasker Suzanne P, Fodili Faouzia, Bos Reinhard, Tekstra Janneke, van Laar Jacob M 5 apr 2020, In: Trials. 21

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy

Safy-Khan Mary, Jacobs Johannes W.G., De Hair Maria J.H., Welsing Paco M.J., Edwardes Michael D., Teitsma Xavier M., Luder Yves, Devenport Jenny, Van Laar Jacob M., Pethoe-Schramm Attila, Bijlsma Johannes W.J. apr 2020, In: Annals of the Rheumatic Diseases. 79 , p. 460-463 4 p.

All research output